BNP Paribas Financial Markets
ADPT icon

BNP Paribas Financial Markets’s Adaptive Biotechnologies ADPT Stock Holding History

BNP Paribas Financial Markets’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13M Buy
81,382
+12,320
+18% +$196K ﹤0.01% 3055
2025
Q4 		$1.12M Buy
69,062
+8,762
+15% +$143K ﹤0.01% 3021
2025
Q3 		$902K Buy
60,300
+20,384
+51% +$248K ﹤0.01% 3199
2025
Q2 		$465K Buy
39,916
+31,255
+361% +$284K ﹤0.01% 3366
2025
Q1 		$64.4K Sell
8,661
-22,051
-72% -$169K ﹤0.01% 4204
2024
Q4 		$184K Sell
30,712
-25,108
-45% -$138K ﹤0.01% 3912
2024
Q3 		$286K Buy
55,820
+45,521
+442% +$198K ﹤0.01% 3101
2024
Q2 		$37.3K Sell
10,299
-52,842
-84% -$168K ﹤0.01% 3517
2024
Q1 		$203K Buy
63,141
+20,710
+49% +$80.1K ﹤0.01% 3244
2023
Q4 		$208K Sell
42,431
-35,332
-45% -$161K ﹤0.01% 3196
2023
Q3 		$424K Buy
77,763
+47,956
+161% +$317K ﹤0.01% 2808
2023
Q2 		$200K Sell
29,807
-35,695
-54% -$265K ﹤0.01% 3016
2023
Q1 		$578K Buy
65,502
+25,953
+66% +$229K ﹤0.01% 2649
2022
Q4 		$302K Sell
39,549
-44,514
-53% -$346K ﹤0.01% 2838
2022
Q3 		$599K Buy
84,063
+46,095
+121% +$434K ﹤0.01% 2855
2022
Q2 		$307K Buy
37,968
+29,483
+347% +$259K ﹤0.01% 2905
2022
Q1 		$118K Buy
8,485
+5,359
+171% +$84.3K ﹤0.01% 3321
2021
Q4 		$87.7K Buy
3,126
+3
+0.1% +$92 ﹤0.01% 3633
2021
Q3 		$106K Buy
3,123
+1,447
+86% +$52.3K ﹤0.01% 3248
2021
Q2 		$68.5K Sell
1,676
-1,655
-50% -$64.3K ﹤0.01% 3152
2021
Q1 		$134K Buy
3,331
+594
+22% +$32.2K ﹤0.01% 3220
2020
Q4 		$162K Buy
2,737
+1,557
+132% +$80.3K ﹤0.01% 2979
2020
Q3 		$57.4K Sell
1,180
-1,774
-60% -$74.6K ﹤0.01% 3402
2020
Q2 		$143K Buy
2,954
+1,340
+83% +$48.9K ﹤0.01% 2629
2020
Q1 		$44.8K Buy
1,614
+825
+105% +$23K ﹤0.01% 3594
2019
Q4 		$23.6K Buy
789
+119
+18% +$3.42K ﹤0.01% 3949
2019
Q3 		$20.7K Buy
+670
New +$27.3K ﹤0.01% 3935

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets's ADPT Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Adaptive Biotechnologies (ADPT) stake by 18% in Q1 2026, buying an estimated $196K and bringing the position to 81,382 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3055.

BNP Paribas Financial Markets first reported a position in ADPT in Q3 2019 and has held it in 27 quarters since. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • BNP Paribas Financial Markets held 81,382 shares of Adaptive Biotechnologies worth $1.13M as of Q1 2026.
  • BNP Paribas Financial Markets bought 12,320 Adaptive Biotechnologies shares in Q1 2026, an estimated $196K.
  • Adaptive Biotechnologies made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3055 holding.
  • BNP Paribas Financial Markets first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 27 quarters since.
  • 295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.